An interventional study of Electro-acupuncture and Laser Acupuncture in Retinitis Pigmentosa, sponsored by Nova Southeastern University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Nova Southeastern University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 39th largest by planned enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2014, is one of 19 with no phase, reaches primary completion later than 11 of the 41 other live ones, and was the 40th registered.
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 27 across 180 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 70 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
Nova Southeastern University is the lead sponsor of 80 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Nova Southeastern University has 1 study filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.
Retinitis pigmentosa (RP) is a slowly progressive retinal degeneration for which there is no proven treatment. Patients are interested in trying alternative therapies to try to reduce their vision loss, but only limited research evidence exists to support their use and potential benefit. The goal of this research project is to gain a better understanding of possible changes in ocular and retinal blood flow and measures of vision in RP patients receiving two promising therapies, electroacupuncture and transcorneal electrical stimulation. We are currently only doing transcorneal electrical stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
Device: Electro-acupuncture
No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
Device: Sham Electro-acupuncture
Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
Device: Laser Acupuncture
An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
Device: Sham laser acupuncture
Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
Device: Transcorneal Electrical Stimulation
Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
Device: Sham transcorneal electrical stimulation
Significant changes from baseline in Goldmann visual field area in both eyes
Using Haig-Streit Octopus perimeter
Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Significant changes from baseline in best-corrected ETDRS visual acuity at both 2 weeks and 6 weeks post-intervention initiation
Using Pelli-Robson visual acuity charts
Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Changes in Macular edema Optical Coherence Tomography (OCT)
Using Optical Coherence Tomography
Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Significant changes from baseline in contrast sensitivity at both 2 weeks and 6 weeks post-intervention initiation
Using Adaptive Sensory Technology Quick CSF
Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Significant changes from baseline in Dark adaptation function at both 2 weeks and 6 weeks post-intervention initiation
Using the AdaptDx by Maculogix
Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Started Aug 2014 (actual). Primary completion is estimated for Dec 2026, 148 months after the start.
Of 30 interventional studies with no phase under Retinitis Pigmentosa, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 154. This study's planned 148 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Southeastern University